The NKF and IGANF conducted an EL-PFDD meeting on IgAN to inform the FDA on the patient perspective on living with this disease. Understanding the patient perspective will help the FDA when it decides whether to approve potential medicines for IgAN.
On August 19, 2019, the National Kidney Foundation and the IGA Nephropathy Foundation of America held an EL-PFDD Meeting on IgA nephropathy.
You can:
Read the Voice of the Patient Report
Listen to the meeting recording here
Read the meeting transcript here
Ten Years Follow-up of STOP-IgAN Trial